SSH1 and glioblastoma: Similarly, our PFS analyses demonstrated that high SSH1 expression increased the likelihood of disease progression in patients with LIHC 1.6-fold (HR (95% CI) = 1.57 (1.1 - 2.24)), and this was second only to UCEC (HR (95% CI) = 2.48 (1.18 - 5.23)) and glioblastoma (GBM: HR (95% CI) = 1.76 (1.12 - 2.76)) (Figure 2E).